|

CRANE CO (CR)

US2244081046 - Common Stock

107.4  +0.73 (+0.68%)

After market: 107.4 0 (0%)

Fundamental Rating

5

Taking everything into account, CR scores 5 out of 10 in our fundamental rating. CR was compared to 133 industry peers in the Machinery industry. CR gets an excellent profitability rating and is at the same time showing great financial health properties. CR has a expensive valuation and it also scores bad on growth.



7

1. Profitability

1.1 Basic Checks

In the past year CR was profitable.
In the past year CR had a positive cash flow from operations.
In the past 5 years CR has always been profitable.
CR had a positive operating cash flow in 4 of the past 5 years.

1.2 Ratios

The Return On Assets of CR (11.29%) is better than 86.36% of its industry peers.
CR's Return On Equity of 19.27% is amongst the best of the industry. CR outperforms 81.82% of its industry peers.
CR has a Return On Invested Capital of 11.56%. This is in the better half of the industry: CR outperforms 75.00% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for CR is below the industry average of 10.32%.
The last Return On Invested Capital (11.56%) for CR is above the 3 year average (6.64%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 11.29%
ROE 19.27%
ROIC 11.56%
ROA(3y)5.96%
ROA(5y)5.84%
ROE(3y)14.68%
ROE(5y)15.02%
ROIC(3y)6.64%
ROIC(5y)7.96%

1.3 Margins

The Profit Margin of CR (12.14%) is better than 84.09% of its industry peers.
CR's Profit Margin has improved in the last couple of years.
The Operating Margin of CR (13.60%) is better than 74.24% of its industry peers.
CR's Operating Margin has declined in the last couple of years.
With a decent Gross Margin value of 38.56%, CR is doing good in the industry, outperforming 78.79% of the companies in the same industry.
CR's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 13.6%
PM (TTM) 12.14%
GM 38.56%
OM growth 3Y-6.41%
OM growth 5Y-4.71%
PM growth 3Y34.22%
PM growth 5Y9.75%
GM growth 3Y-0.79%
GM growth 5Y-0.76%

8

2. Health

2.1 Basic Checks

CR has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
CR has less shares outstanding than it did 1 year ago.
Compared to 5 years ago, CR has less shares outstanding
Compared to 1 year ago, CR has a worse debt to assets ratio.

2.2 Solvency

An Altman-Z score of 6.29 indicates that CR is not in any danger for bankruptcy at the moment.
With an excellent Altman-Z score value of 6.29, CR belongs to the best of the industry, outperforming 84.85% of the companies in the same industry.
The Debt to FCF ratio of CR is 1.44, which is an excellent value as it means it would take CR, only 1.44 years of fcf income to pay off all of its debts.
The Debt to FCF ratio of CR (1.44) is better than 84.09% of its industry peers.
A Debt/Equity ratio of 0.19 indicates that CR is not too dependend on debt financing.
The Debt to Equity ratio of CR (0.19) is better than 69.70% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.19
Debt/FCF 1.44
Altman-Z 6.29
ROIC/WACC1.2
WACC9.64%

2.3 Liquidity

A Current Ratio of 2.55 indicates that CR has no problem at all paying its short term obligations.
CR has a better Current ratio (2.55) than 64.39% of its industry peers.
CR has a Quick Ratio of 1.70. This is a normal value and indicates that CR is financially healthy and should not expect problems in meeting its short term obligations.
With a decent Quick ratio value of 1.70, CR is doing good in the industry, outperforming 73.48% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.55
Quick Ratio 1.7

1

3. Growth

3.1 Past

CR shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -19.21%.
Measured over the past years, CR shows a quite strong growth in Earnings Per Share. The EPS has been growing by 11.19% on average per year.
The Revenue for CR has decreased by -45.27% in the past year. This is quite bad
Measured over the past years, CR shows a decrease in Revenue. The Revenue has been decreasing by -6.09% on average per year.
EPS 1Y (TTM)-19.21%
EPS 3Y8.61%
EPS 5Y11.19%
EPS growth Q2Q-44.62%
Revenue 1Y (TTM)-45.27%
Revenue growth 3Y-14.74%
Revenue growth 5Y-6.09%
Revenue growth Q2Q-65.78%

3.2 Future

Based on estimates for the next years, CR will show a decrease in Earnings Per Share. The EPS will decrease by -2.40% on average per year.
The Revenue is expected to decrease by -4.71% on average over the next years.
EPS Next Y5.27%
EPS Next 2Y-20.87%
EPS Next 3Y-10.48%
EPS Next 5Y-2.4%
Revenue Next Year-1.07%
Revenue Next 2Y-19.12%
Revenue Next 3Y-11.42%
Revenue Next 5Y-4.71%

3.3 Evolution

The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.

2

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings ratio is 19.49, which indicates a rather expensive current valuation of CR.
The rest of the industry has a similar Price/Earnings ratio as CR.
The average S&P500 Price/Earnings ratio is at 24.54. CR is valued slightly cheaper when compared to this.
A Price/Forward Earnings ratio of 22.27 indicates a rather expensive valuation of CR.
CR's Price/Forward Earnings is on the same level as the industry average.
When comparing the Price/Forward Earnings ratio of CR to the average of the S&P500 Index (20.22), we can say CR is valued inline with the index average.
Industry RankSector Rank
PE 19.49
Fwd PE 22.27

4.2 Price Multiples

Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of CR indicates a slightly more expensive valuation: CR is more expensive than 65.91% of the companies listed in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of CR is on the same level as its industry peers.
Industry RankSector Rank
P/FCF 35.17
EV/EBITDA 19.1

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates CR does not grow enough to justify the current Price/Earnings ratio.
CR has a very decent profitability rating, which may justify a higher PE ratio.
A cheap valuation may be justified as CR's earnings are expected to decrease with -10.48% in the coming years.
PEG (NY)3.7
PEG (5Y)1.74
EPS Next 2Y-20.87%
EPS Next 3Y-10.48%

3

5. Dividend

5.1 Amount

CR has a yearly dividend return of 0.69%, which is pretty low.
Compared to an average industry Dividend Yield of 1.81, CR has a dividend in line with its industry peers.
With a Dividend Yield of 0.69, CR pays less dividend than the S&P500 average, which is at 2.55.
Industry RankSector Rank
Dividend Yield 0.69%

5.2 History

The dividend of CR has a limited annual growth rate of 5.56%.
CR has paid a dividend for at least 10 years, which is a reliable track record.
CR has not decreased their dividend for at least 10 years, which is a reliable track record.
Dividend Growth(5Y)5.56%
Div Incr Years1
Div Non Decr Years19

5.3 Sustainability

263.23% of the earnings are spent on dividend by CR. This is not a sustainable payout ratio.
CR's earnings are declining while the Dividend Rate has been growing. This means the dividend growth is most likely not sustainable.
DP263.23%
EPS Next 2Y-20.87%
EPS Next 3Y-10.48%

CRANE CO

NYSE:CR (12/11/2023, 3:00:52 PM)

After market: 107.4 0 (0%)

107.4

+0.73 (+0.68%)

Chartmill FA Rating
GICS SectorIndustrials
GICS IndustryGroupCapital Goods
GICS IndustryMachinery
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap6.10B
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield 0.69%
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE 19.49
Fwd PE 22.27
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)3.7
PEG (5Y)1.74
Profitability
Industry RankSector Rank
ROA 11.29%
ROE 19.27%
ROCE
ROIC
ROICexc
ROICexgc
OM 13.6%
PM (TTM) 12.14%
GM 38.56%
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.93
Health
Industry RankSector Rank
Debt/Equity 0.19
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 2.55
Quick Ratio 1.7
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-19.21%
EPS 3Y8.61%
EPS 5Y
EPS growth Q2Q
EPS Next Y5.27%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-45.27%
Revenue growth 3Y-14.74%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y